Regulus Reports Hep C Candidate Shines in Phase 2 Trial

Regulus Therapeutics has unveiled interim results from a Phase 2 study of its hepatitis C candidate RG-101, which saw 97 percent of patients achieve a sustained viral response at eight weeks of treatment.

The study evaluated a shortened four-week treatment of a subcutaneous 2-mg dose of RG-101, followed by four weeks of treatment of once-daily Harvoni, Olysio or Daklinza in treatment-naïve genotype 1 and 4 HCV patients. For patients who reached 12 weeks of treatment, 100 percent achieved a sustained viral response.

Regulus officials have said the company is planning to accelerate the development program for RG-101 and seek clarity for an approval pathway.